ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Condition(s):Metastatic Hormone-sensitive Prostate CancerLast Updated:June 1, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Metastatic Hormone-sensitive Prostate CancerLast Updated:June 1, 2023Completed
Condition(s):Prostate CancerLast Updated:January 19, 2015Withdrawn
Condition(s):Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate CancerLast Updated:May 25, 2023Active, not recruiting
Condition(s):Prostate CancerLast Updated:February 6, 2024Active, not recruiting
Condition(s):Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Last Updated:February 29, 2024Recruiting
Condition(s):Prostate CancerLast Updated:June 26, 2019Completed
Condition(s):Prostate CancerLast Updated:March 19, 2024Completed
Condition(s):Prostate CancerLast Updated:September 22, 2023Completed
Condition(s):Prostate CancerLast Updated:April 18, 2023Active, not recruiting
Condition(s):Prostate Adenocarcinoma; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8Last Updated:February 7, 2024Suspended
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.